Ocular Therapeutix director receives RSU and option grants
Ocular Therapeutix director Adrienne L. Graves received new equity awards as part of her board compensation.
Rhea-AI Filing Summary
Ocular Therapeutix director Adrienne L. Graves received new equity awards as part of her board compensation. She was granted 14,000 restricted stock units, each representing one share of common stock, increasing her direct common stock holdings to 64,000 shares after the award.
She was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest 100% on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving on the board.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 58,000 shares
Grant/Award
2 txns
Insider
Graves Adrienne L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 14,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,000 contracts (Direct);
Common Stock — 64,000 shares (Direct)
Footnotes (2)
- F1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
- F2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Key Figures
RSU grant: 14,000 shares
Options granted: 44,000 shares
Option exercise price: $8.74 per share
+3 more
6 metrics
RSU grant
14,000 shares
Restricted stock units granted June 10, 2026
Options granted
44,000 shares
Stock options granted June 10, 2026
Option exercise price
$8.74 per share
Stock options on common stock
Option expiration
June 9, 2036
Expiration date for 44,000 stock options
Shares held after grant
64,000 shares
Total common stock directly held post-award
Vesting schedule
1-year cliff
100% vesting on first anniversary or before next annual meeting
Key Terms
restricted stock units ("RSUs"), 2021 Stock Incentive Plan, Stock Option (Right to Buy), vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Incentive Plan financial
"granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders regulatory
"immediately prior to the next annual meeting of stockholders occurring after the grant date"
FAQ
What equity awards did Ocular Therapeutix (OCUL) director Adrienne Graves receive?
Adrienne Graves received 14,000 restricted stock units and stock options for 44,000 shares. The awards are part of her board compensation and give her additional exposure to Ocular Therapeutix common stock subject to vesting conditions over the coming year.
When do Adrienne Graves’ new RSUs in Ocular Therapeutix (OCUL) vest?
The 14,000 restricted stock units vest 100% one year after the June 10, 2026 grant date. They may also vest earlier, immediately before the next annual stockholder meeting, if she continues serving on Ocular Therapeutix’s board of directors through that time.
What are the terms of Adrienne Graves’ new stock options in Ocular Therapeutix (OCUL)?
She received options to buy 44,000 shares of Ocular Therapeutix common stock at an $8.74 exercise price. These options vest on the same schedule as the RSUs and expire on June 9, 2036, providing a long-dated incentive tied to future share performance.
Are Adrienne Graves’ new Ocular Therapeutix (OCUL) awards open-market purchases?
No, the Form 4 describes compensation-related grants, not open-market buying. The RSUs and stock options were awarded under Ocular Therapeutix’s 2021 Stock Incentive Plan as amended, with vesting tied to her continued service on the company’s board of directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
